Klinik và Di truyền của Neurofibromatose loại 1

Brems H, Chmara M, Sahbatou M et al (2007) Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat Genet 39:1120–1126

De Luca A, Bottillo I, Sarkozy A et al (2005) NF1 gene mutations represent the major molecular event underlying neurofibromatosis-Noonan syndrome. Am J Hum Genet 77:1092–1101

De Raedt T, Brems H, Wolkenstein P et al (2003) Elevated risk for MPNST in NF1 microdeletion patients. Am J Hum Genet 72:1288–1292

De Schepper S, Maertens O, Callens T et al (2008) Somatic mutation analysis in NF1 café au lait spots reveals two NF1 hits in the melanocytes. J Invest Dermatol 128:1050–1053

Dilworth JT, Kraniak JM, Wojtkowiak JW et al (2006) Molecular targets for emerging anti-tumor therapies for neurofibromatosis type 1. Biochem Pharmacol 72:1485–1492

Evans DG, Baser ME, McGaughran J et al (2002) Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 39:311–314

Ferner RE, Huson SM, Thomas N et al (2007) Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 44:81–88

Huson SM, Hughes RAC (1994) The neurofibromatoses. Chapman & Hall, London, pp 160–203

Hyman SL, Shores A, North KN (2005) The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Neurology 65:1037–1044

Johannessen CM, Johnson BW, Williams SM et al (2008) TORC1 is essential for NF1-associated malignancies. Curr Biol 18:56–62

Kehrer-Sawatzki H, Cooper DN (2008) Mosaicism in sporadic neurofibromatosis type 1: variations on a theme common to other hereditary cancer syndromes? J Med Genet 45:622–631

Kluwe L, Siebert R, Gesk S et al (2004) Screening of 500 unselected neurofibromatosis 1 patients for deletions of the NF1 gene. Hum Mutat 23:111–116

Koike K, Matsuda K (2008) Recent advances in the pathogenesis and management of juvenile myelomonocytic leukaemia. Br J Haematol 141:567–575

Korf BR (1992) Diagnostic outcome in children with multiple café au lait spots. Pediatrics 90:924–927

Kratz CP, Niemeyer CM, Jüttner E et al (2008) Childhood T-cell non-Hodgkin’s lymphoma, colorectal carcinoma and brain tumor in association with café-au-lait spots caused by a novel homozygous PMS2 mutation. Leukemia 22:1078–1080

Li W, Cui Y, Kushner SA et al (2005) The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr Biol 15:1961–1967

López-Correa C, Dorschner M, Brems H et al (2001) Recombination hotspot in NF1 microdeletion patients. Hum Mol Genet 10:1387–1392

Messiaen LM, Callens T, Mortier G et al (2000) Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Hum Mutat 15:541–555

NIH (1988) Neurofibromatosis. National Health Consensus Development Conference Statement, Bethesda, MD, USA, July 13–15, 1987. Neurofibromatosis 1:172–178

Pasmant E, Sabbagh A, Hanna N et al (2009) SPRED1 germline mutations caused a neurofibromatosis type 1 overlapping phenotype. J Med Genet 46(7):425–430

Steinmann K, Cooper DN, Kluwe L et al (2007) Type-2 NF1 deletions are highly unusual by virtue of the absence of non-allelic homologous recombination hotspots and an apparent preference for female mitotic recombination. Am J Hum Genet 81:1201–1220

Stevenson DA, Zhou H, Ashrafi S et al (2006) Double inactivation of NF1 in tibial pseudarthrosis. Am J Hum Genet 79:143–148

Upadhyaya M, Huson SM, Davies M et al (2007) An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970–2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation. Am J Hum Genet 80:140–151